De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients

Area of Science:

• Immunology
• Transplantation Medicine
• Clinical Research

Background:

• The role of de novo donor-specific HLA antibodies (DSA) in liver transplantation is not well understood, with prior research focusing on preformed antibodies.
• Understanding de novo DSA is crucial for improving long-term outcomes in liver transplant recipients.

Purpose of the Study:

• To investigate the incidence and clinical significance of de novo donor-specific HLA antibodies (DSA) in adult liver transplant recipients.
• To identify risk factors associated with the development of de novo DSA post-transplantation.

Main Methods:

• A retrospective cohort study of 749 adult liver transplant recipients.
• Analysis of pre- and post-transplant serum samples for donor-specific HLA antibodies (DSA).
• Multivariable modeling to assess risk factors and outcomes related to de novo DSA.

Main Results:

• 8.1% of patients developed de novo DSA within 1 year post-transplant, predominantly against HLA class II (DQ) antigens.
• Cyclosporine use, low calcineurin inhibitor levels, high MELD score (>15), and older recipient age (>60) were associated with de novo DSA.
• De novo DSA at 1 year significantly correlated with reduced patient and graft survival.

Conclusions:

• De novo DSA development after liver transplantation is an independent risk factor for patient mortality and graft loss.
• Identifying and managing de novo DSA is critical for enhancing long-term success in liver transplantation.